TABLE 2.
A. fumigatus‐specific IgE | ABPM‐Sc | ABPA | p* | |
---|---|---|---|---|
Negative n = 10 | Positive n = 19 | n = 46 | ||
Age at onset of ABPM, y | 65 (44–77) | 57 (38–66) | 67 (51–71) | 0.11 |
Women | 7 (70) | 12 (63) | 27 (59) | 0.84 |
Asthma* | 3 (30) | 11 (58) | 32 (70) | 0.07 |
Treatment step (1–2/3–5, n [%]) | 3/0 (100/0) | 6/4 (60/40) | 8/22 (27/73) | 0.01 |
Laboratory data at diagnosis | ||||
Peripheral blood eosinophil counts (/μL) | 523 (263–750) | 686 (500–1409) | 983 (472–1505) | 0.12 |
Serum IgE levels* (IU/mL) | 562*** (194–1571) | 2366 (1363–6504) | 1954 (530–4583) | 0.03 |
A. fumigatus‐specific IgE*, UA/mL | 0.09**,*** (0.05–0.16) | 3.13 (0.85–5.66) | 11.20 (3.29–30.05) | <0.001 |
A. fumigatus‐specific precipitin/IgG‐positive, n (%) | 1** a (17) | 6** b (38) | 40 (87) | <0.001 |
S. commune‐specific IgE‐positive, n (%) | 5 a (83) | 6 a (100) | NA | |
S. commune‐specific precipitin/IgG‐positive, n (%) | 6 c (86) | 5 a (83) | NA | |
Thoracic computed tomography | ||||
Central bronchiectasis, n (%) | 9 (90) | 16 (84) | 28 (61) | 0.08 |
Mucus plugs, n (%) | 10 (100) | 17 (90) | 40 (87) | 0.76 |
High attenuation mucus, n (%) | 7 (78) | 14 (74) | 27 (59) | 0.43 |
Infiltration/GGO, n (%) | 7 (70) | 16 (84) | 43 (94) | 0.08 |
Fibrotic/cystic change, n (%) | 0 (0) | 0 (0) | 8 (17) | 0.08 |
FEV1, %predicted* | 103 (83–112) | 93 (74–107) | 80 (65–92) | 0.02 |
Note: Values are medians (interquartile range) or the proportion of patients in each study group, if not otherwise specified.
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; ABPM‐Sc, ABPM caused by S. commune; FEV1, forced expiratory volume in 1 s; GGO, ground‐glass opacity; Ig, immunoglobulin.
n = 6.
n = 16.
n = 7.
*Among the three groups, **p < 0.05, versus ABPA, ***p < 0.05 versus ABPM‐Sc with sensitization to A. fumigatus.